Clinical trials: RAS Mutation
Colorectal Cancer Metastatic, Liver Metastases
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Patients presenting with multiple innumerable liver metastases will probably never come to resection, however, for all others, including patients with numerous multiple metastases or large metastases, resection should be…
- Conditions
- Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer
- Trial name
- BOS3 (NCT01646554)
- Testing
- Modified FOLFOX6, Aflibercept, Surgery
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma, Solid Tumor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
This is a subprotocol of Master Protocol DAY101-102 and is a Phase 1b/2, multi-center, open label subprotocol of participants ≥12 years of age, with recurrent or progressive solid tumors with alterations in the key proteins of…
- Conditions
- Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer
- Trial name
- NCT07121829
- Testing
- Tovorafenib, Tovorafenib Drug: Pimasertib
- Where
- 10 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Solid Tumors (Phase 1), RAS Mutation
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations.
- Trial name
- NCT07252479
- Testing
- AN9025 oral capsule
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
This is an open-label, multicenter Phase Ib/II clinical study evaluating GFH276 in combination with tislelizumab plus pemetrexed/platinum based regimen as first-line therapy in participants with locally advanced or metastatic…
- Trial name
- GFH276X1203 (NCT07846358)
- Testing
- GFH276, with or without Tislelizumab, Pemetrexed
- Volunteers
- 84 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Solid Tumor, Adult
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors.
- Trial name
- NCT03919292
- Testing
- Neratinib, Divalproex Sodium
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Virginia Commonwealth University
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
This is a Phase 2, multicenter, randomized, controlled, open-label trial of pimasertib versus dacarbazine aimed to confirm the activity of pimasertib in previously untreated subjects with N-Ras mutated locally advanced or…
- Trial name
- NCT01693068
- Testing
- Pimasertib, Dacarbazine
- Where
- 101 sites in United States, Australia and 12 more
- Volunteers
- 194 people
- Sponsor
- EMD Serono
Chronic Myelomonocytic Leukemia (CMML)
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles.
- Trial name
- CONCERTO (NCT04409639)
- Testing
- Cobimetinib
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Utah
Colorectal Cancer
RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer
This study will evaluate the concordance of RAS mutation detection between the results obtained from circulating tumor DNA and those obtained with the "standard" method (testing from tumor tissue).
- Trial name
- RASANC (NCT02502656)
- Where
- 14 sites in France
- Volunteers
- 425 people
- Sponsor
- Association des Gastroentérologues Oncologues
Colorectal Cancer, Metastatic Colorectal Cancer
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
This study is a prospective, randomized phase III, to evaluate if in patients with mCRC RAS/BRAF wild type on tumor tissue and RAS mutations on liquid biopsy, treating in first line with antibody anti-VEGF (bevacizumab) plus…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation
- Trial name
- LIBImAb (NCT04776655)
- Testing
- Bevacizumab, Cetuximab, 5-FU
- Where
- 4 sites in Italy
- Volunteers
- 280 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Oncology, MEK Mutation
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway…
- Conditions
- Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation
- Trial name
- NST-628 (NCT06326411)
- Testing
- NST-628
- Where
- 23 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Nested Therapeutics, Inc
Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune…
- Conditions
- Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer
- Trial name
- NCT00019006
- Testing
- Detox-B adjuvant, ras peptide cancer vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R
- Trial name
- AMPLIFY-7P (NCT05726864)
- Testing
- ELI-002 7P
- Where
- 28 sites in United States
- Volunteers
- 158 people
- Sponsor
- Elicio Therapeutics
Colorectal Neoplasms, Chemotherapy Effect
Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
Patients meeting the inclusion criteria will be randomized 1:1 into Cohort A (n ≈ 177) or Cohort BC (n ≈ 177). Cohort A is the control: patients receive combination chemotherapy with FOLFOX plus anti-EGFR therapy (panitumumab or…
- Conditions
- Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation
- Trial name
- CRC01 (NCT06226857)
- Testing
- Cetuximab
- Where
- 3 sites in Russia
- Volunteers
- 355 people
- Sponsor
- City Clinical Oncology Hospital No 1
Pancreatic Cancer, PDAC
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- RASolute 304 (NCT07252232)
- Testing
- daraxonrasib
- Where
- 86 sites in United States, Canada and 8 more
- Volunteers
- 500 people
- Sponsor
- Revolution Medicines, Inc.
Pancreatic Ductal Adenocarcinoma, KRAS G12D
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
This is an open-label expanded access protocol (EAP) of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P])…
- Conditions
- Pancreatic Ductal Adenocarcinoma, KRAS G12D, KRAS G12V, KRAS G12S
- Trial name
- AMPLIFY-EAP (NCT07083479)
- Testing
- ELI-002 7P
- Sponsor
- Elicio Therapeutics
RAS Mutation
Hematological Anomalies in Children With Rasopathy
During childhood, patients with RASopathies (Noonan syndrome and related diseases) can harbor various hematological anomalies ranging from isolated monocytosis, myelemia, thrombocytopenia or splenomegaly to myeloproliferative…
- Trial name
- RAS-HEMATO (NCT04286360)
- Where
- 14 sites in France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Neoplasm Metastasis
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
- Trial name
- NCT02313012
- Testing
- CC-90003
- Where
- 5 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- Celgene
Metastatic Colorectal Cancer
Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation
A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in combination with irinotecan in the second line treatment or more of metastatic colorectal cancer with K-RAS mutation.
- Trial name
- NEXIRI (NCT00989469)
- Testing
- Nexavar (Sorafenib) and irinotecan (Campto)
- Where
- 5 sites in France
- Volunteers
- 64 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Pancreatic Cancer
Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis
Pancreatic cancers represent a challenge for the multidisciplinal team. A patient-tailored treatment plan requires an accurate preoperative staging.
- Trial name
- NCT03524677
- Testing
- Liquid Biopsy
- Where
- 3 sites in Ireland, Italy
- Volunteers
- 50 people
- Sponsor
- University of Roma La Sapienza